| Date Filed | Type | Description |
| 06/07/2023 |
4
| O'Neill Gilmore Neil (CEO) has filed a Form 4 on Editas Medicine, Inc.|
Txns:
| Sold 6,486 shares
@ $9.5032, valued at
$61.6k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/06/2023 |
4
| O'Neill Gilmore Neil (CEO) has filed a Form 4 on Editas Medicine, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 150,000 options to buy
@ $8.72, valued at
$1.3M
|
|
| 06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/22/2021 |
4
| O'Neill Gilmore Neil (Director) has filed a Form 4 on Aptinyx Inc.|
Txns:
| Granted 80,000 options to buy
@ $2.26, valued at
$180.8k
|
|
| 10/22/2021 |
3
| O'Neill Gilmore Neil (Director) has filed a Form 3 on Aptinyx Inc. |
| 06/28/2021 |
4
| O'Neill Gilmore Neil (Director) has filed a Form 4 on Unity Biotechnology, Inc.|
Txns:
| Granted 13,425 options to buy
@ $4.18, valued at
$56.1k
|
|
| 03/10/2021 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 03/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/14/2020 |
4
| O'Neill Gilmore Neil (Director) has filed a Form 4 on Unity Biotechnology, Inc.|
Txns:
| Granted 50,000 options to buy
@ $6.12, valued at
$306k
|
|
| 12/14/2020 |
3
| O'Neill Gilmore Neil (Director) has filed a Form 3 on Unity Biotechnology, Inc. |
| 02/28/2020 |
4
| O'Neill Gilmore Neil (EVP, R&D & CMO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 6,700 shares
@ $0
Granted 37,500 options to buy
@ $114.47, valued at
$4.3M
|
|
| 05/24/2019 |
4
| O'Neill Gilmore Neil (EVP, R&D & CMO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,630 shares
@ $119.31, valued at
$552.4k
Exercised 12,000 restricted stock units
@ $0 |
|
| 03/04/2019 |
4
| O'Neill Gilmore Neil (EVP, R&D & CMO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 55,000 options to buy
@ $145.48, valued at
$8M
|
|
| 06/11/2018 |
4
| O'Neill Gilmore Neil (SVP & Chief Medical Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $96.23, valued at
$9.6M
Granted 12,000 restricted stock units
@ $0 |
|
| 06/11/2018 |
3
| O'Neill Gilmore Neil (SVP & Chief Medical Officer) has filed a Form 3 on Sarepta Therapeutics, Inc. |